2-甲基-6-(吡咯烷-1-基甲基)吡啶 | 125104-68-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-甲基-6-(吡咯烷-1-基甲基)吡啶
• 英文名称: 2-methyl-6-(1-pyrrolidinylmethyl)pyridine
• 英文别名: 2-(pyrrolidine)methyl-6-methylpyridine；6-methyl-2-(pyrrolidin-1-yl)methyl pyridine；2-Methyl-6-[(pyrrolidin-1-yl)methyl]pyridine；2-methyl-6-(pyrrolidin-1-ylmethyl)pyridine
• CAS: 125104-68-9
• 化学式: C₁₁H₁₆N₂
• 分子量: 176.261
• InChiKey: UWGGDBZLFAXETC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-甲基-6-(吡咯烷-1-基甲基)吡啶 在 正丁基锂 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 为溶剂， 反应 6.0h， 生成
  参考文献：
  名称：

  基于（手性）吡咯烷的PNN配体钌配合物：合成，结构和动态立体化学

  摘要：

  我们报告了基于N侧臂的非手性（吡咯烷）和手性（（R，R）-2,5-二甲基吡咯烷和（R）-2-甲基吡咯烷）取代基的基于二甲基吡啶的PNN型金属钳配合物的合成钳配体。以具有芳香族吡啶配体主链的六配位饱和Ru钳（PNN）Ru（H）（CO）（Cl）为起始原料，用强碱（KO t Bu）处理生成相应的脱芳族钳分子（PNN'）Ru（H）（CO）。光谱，晶体学和计算研究表明，手性吡咯烷基团的C中心手性对Ru（和N（在（R）-2-甲基吡咯烷）反映在溶液中这些Ru络合物的非对映异构体的平衡分布中。我们的数据显示，这类化合物中基于N和Ru的立体异构中心在立体化学上不稳定，并且讨论了差向异构化的机制。提出通过脱芳构化的Ru（0）中间体发生Ru芳构化复合物中Ru中心的转化，在该中间体中Ru结合的氢化物转移至配体。支持这一点的是通过与CO反应获得的密切相关的Ru（0）物种的光谱表征。在对映选择性oxa-Michael

  DOI：

  10.1021/acs.organomet.9b00765
• 作为产物：
  描述：

  6-甲基-2-吡啶基甲醇 生成 2-甲基-6-(吡咯烷-1-基甲基)吡啶
  参考文献：
  名称：

  N-Acylated azacyclic compounds, processes for their preparations and their use as medications

  摘要：

  化合物，或其配合物或盐，其化学式为（I）：其中：RCO是一种酰基，其中基团R包含一个取代或未取代的碳环芳香族或杂环芳香族环；R₁和R₂分别是氢、C₁₋₆烷基、C₂₋₆烯基、C₃₋₆环烷基或C₄₋₁₂环烷基烷基，或者一起形成一个C₂₋₈支链或线性聚亚甲基或C₂₋₆烯基烷基，可选地取代有一个杂原子；R₃是氢、C₁₋₆烷基或苯基，或R₃与R₁一起形成一个-(CH₂)₃-或-(CH₂)₄-基团；R₄和R₅分别是氢、羟基、卤素、C₁₋₆烷基或芳基，前提是R₄和R₅不能同时为氢；p是从1到4的整数，对于治疗疼痛或低钠血症状是有用的。

  公开号：

  EP0447704A1

文献信息

• Spiropiperidine derivatives
  申请人：Glaxo Group Limited

  公开号：US05114945A1

  公开（公告）日：1992-05-19

  Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents hydroxy, C.sub.1-6 alkyl, C.sub.1-6 hydroxyalkyl, C.sub.1-6 carboxyalkyl, phenyl, oxo, amino, carboxy, amido, --NR.sub.4 COR.sub.5 (where R.sub.4 and R.sub.5 both represent C.sub.1-6 alkyl), optionally substituted methylidene or, together with the carbon atom to which it is attached, R.sub.1 forms a 5 or 6-membered ring containing one or more heteroatoms; R.sub.2 and R.sub.3 are the same or different and are C.sub.1-6 alkyl or C.sub.3-6 alkenyl; or --NR.sub.2 R.sub.3 forms a 5-membered (optionally containing an oxygen atom adjacent to the nitrogen) or a 6-membered ring, which ring optionally contains one unit of unsaturation and which is unsubstituted or substituted by hydroxy, oxo, optionally substituted methylidene, --COR.sub.6 (where R.sub.6 represents C.sub.1-6 alkyl, OR, or --NHR, and R represents hydrogen, C.sub.1-6 alkyl, aryl, ar(C.sub.1-6)alkyl) or .dbd.NOR.sub.8 (where R.sub.8 represents C.sub.1-6 alkyl); X represents a direct bond, --CH.sub.2 -- or --CH.sub.2 0--; Ar represents a substituted phenyl moiety; and physiologically acceptable salts thereof. The compounds are indicated as useful for the treatment of pain and cerebral ischemia. Proccesses and intermediates for their preparation and pharmaceutical compositions containing them are also disclosed.

  披露了公式(I)的化合物##STR1##，其中R1代表羟基，C1-6烷基，C1-6羟烷基，C1-6羧烷基，苯基，氧代，氨基，羧基，酰胺基，--NR4COR5（其中R4和R5都代表C1-6烷基），可选地取代亚甲基，或者与它连接的碳原子一起，R1形成一个含有一个或多个杂原子的5或6元环；R2和R3相同或不同，是C1-6烷基或C3-6烯基；或者--NR2R3形成一个5元环（可选地含有一个靠近氮原子的氧原子）或6元环，该环可选地含有一个不饱和单元，并且该环未取代或被羟基，氧代，可选地取代亚甲基，--COR6（其中R6代表C1-6烷基，OR或--NHR，R代表氢，C1-6烷基，芳基，芳(C1-6)烷基）或.dbd.NOR8（其中R8代表C1-6烷基）取代；X代表直接键，--CH2--或-- O--; Ar代表一个取代的苯基部分；以及它们的生理学可接受盐。这些化合物被指出用于治疗疼痛和脑缺血。还披露了它们的制备过程和中间体以及含有它们的药物组合物。
• [EN] BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS BENZÈNESULFONAMIDES ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2017201468A1

  公开（公告）日：2017-11-23

  This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

  本发明涉及苯磺酰胺化合物，包括它们的立体异构体、对映异构体、互变异构体或其混合物；或用于治疗与电压门控钠通道相关的疾病或病症的药用可接受盐、溶剂化物或前药，例如癫痫。
• Piperidine derivatives
  申请人：GLAXO GROUP LIMITED

  公开号：EP0330461A3

  公开（公告）日：1990-10-17

  Compounds are disclosed of formula (I) wherein R₁ represents hydroxy, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ carboxyalkyl, phenyl, oxo, amino, carboxy, amido, -NR₄COR₅ (where R₄ and R₅ both represent C₁₋₆ alkyl), optionally substituted methylidene or, together with the carbon atom to which it is attached, R₁ forms a 5 or 6-membered ring containing one or more heteroatoms; R₂ and R₃ are the same or different and are C₁₋₆ alkyl or C₃₋₆ alkenyl; or -NR₂R₃ forms a 5-membered (optionally containing an oxygen atom adjacent to the nitrogen) or a 6-membered ring, which ring optionally contains one unit of unsaturation and which is unsubstituted or substituted by hydroxy, oxo, optionally substituted methylidene, -COR₆ (where R₆ represents C₁₋₆ alkyl, OR₇ or -NHR₇, and R₇ represents hydrogen, C₁₋₆ alkyl, aryl, ar(C₁₋₆)alkyl) or =NOR₈ (where R₈ represents C₁₋₆ alkyl); X represents a direct bond, -CH₂- or -CH₂O-; Ar represents a substituted phenyl moiety; and physiologically acceptable salts thereof.The compounds are indicated as useful for the treatment of pain and cerebral ischaemia.Processes and intermediates for their preparation and pharmaceutical compositions containing them are also disclosed.

  披露了公式(I)的化合物，其中 R₁代表羟基，C₁₋₆烷基，C₁₋₆羟烷基，C₁₋₆羧烷基，苯基，氧代，氨基，羧基，酰胺，-NR₄COR₅（其中R₄和R₅都代表C₁₋₆烷基），可选地取代的亚甲基，或者与它连接的碳原子一起，R₁形成一个含有一个或多个杂原子的5或6元环； R₂和R₃相同或不同，是C₁₋₆烷基或C₃₋₆烯丙基；或者-NR₂R₃形成一个5元环（可选地含有与氮原子相邻的氧原子）或6元环，该环可选地含有一个不饱和单元，并且该环未取代或被羟基，氧代，可选地取代的亚甲基，-COR₆（其中R₆代表C₁₋₆烷基，OR₇或-NHR₇，R₇代表氢，C₁₋₆烷基，芳基，芳(C₁₋₆)烷基）或=NOR₈（其中R₈代表C₁₋₆烷基）取代； X代表直接键，-CH₂-或-CH₂O-； Ar代表取代的苯基部分； 以及它们的生理可接受盐。 这些化合物被指出用于治疗疼痛和脑缺血。还披露了它们的制备过程和中间体以及含有它们的药物组合物。
• QUINAZOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS
  申请人：Vu Chi B.

  公开号：US20120165330A1

  公开（公告）日：2012-06-28

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新颖的调节sirtuin的化合物及其使用方法。这些调节sirtuin的化合物可用于增加细胞的寿命，并用于治疗和/或预防包括与衰老或应激、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝结障碍、炎症、癌症和/或潮红等在内的各种疾病和疾病。此外，还提供了包含一种调节sirtuin化合物与另一种治疗剂结合的组合物。
• PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS
  申请人：Vu Chi B.

  公开号：US20130190309A1

  公开（公告）日：2013-07-25

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新颖的调节sirtuin的化合物及其使用方法。这些调节sirtuin的化合物可用于延长细胞的寿命，并治疗和/或预防各种疾病和疾病，包括与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症、潮红以及那些会受益于增加线粒体活性的疾病或疾病。还提供了包含sirtuin调节化合物与另一种治疗剂结合的组合物。